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Abstract
As Antiretroviral Therapy (ART) is scaled up in low- and middle-income countries, it is important
to understand Quality of Life (QOL) correlates including disease severity and person
characteristics and to determine the extent of between-country differences among those with HIV.
QOL and medical data were collected from 1,563 of the 1,571 participants at entry into a
randomized clinical trial of ART conducted in the U.S. (n = 203) and 8 resource-limited countries
(n = 1,360) in the Caribbean, South America, Asia, and Africa. Participants were interviewed prior
to initiation of ART using a modified version of the ACTG SF-21, a health-related QOL measure
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including 8 subscales: general health perception, physical functioning, role functioning, social
functioning, cognitive functioning, pain, mental health, and energy/fatigue. Other measures
included demographics, CD4+ lymphocyte count, plasma HIV-1 RNA viral load. Higher quality
of life in each of the 8 QOL subscales was associated with higher CD4+ lymphocyte category.
General health perception, physical functioning, role functioning, and energy/fatigue varied by
plasma HIV-1 RNA viral load categories. Each QOL subscale included significant variation by
country. Only the social functioning subscale varied by sex, with men having greater impairments
than women, and only the physical functioning subscale varied by age category. This was the first
large-scale international ART trial to conduct a standardized assessment of QOL in diverse
international settings, thus demonstrating that implementation of the behavioral assessment was
feasible. QOL indicators at study entry varied with disease severity, demographics, and country.
The relationship of these measures to treatment outcomes can and should be examined in clinical
trials of ART in resource-limited settings using similar methodologies.
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Introduction
In resource-rich countries, antiretroviral therapy (ART) is widely available and HIV is now
seen as a manageable chronic illness rather than a terminal disease. Accordingly, ART
treatment outcomes now also focus on quality of life [1–6] in addition to disease severity
and response to antiretroviral therapy.
Quality of life is a broad construct and can be influenced by many factors such as income,
housing, social support, and life situation. Health-related quality of life, in particular,
encompasses the impact of disease and treatment on a person’s ability to carry out daily
activities and affects well-being. It includes physical, social, cognitive, and psychological
functioning, as well as subjective sense of health, comfort, and well-being [7].
ART availability is now being scaled up in diverse parts of the world, including low- and
middle-income countries, through clinical trials, non-governmental organizations, and
government initiatives such as PEPFAR [8]. HIV clinical trials that seek to assess quality of
life as a secondary trial outcome require pre-treatment data for HIV-infected individuals in
diverse settings. It is well established that quality of life varies with CD4 count and HIV-1
RNA viral load [9–11]. In addition, in various U.S. samples, the AIDS Clinical Trials Group
(ACTG) quality of life measures [12, 13] have been shown to vary with person
characteristics such as gender [14], race [15], and physical ability [16]. However, the degree
to which these associations exist across more diverse settings remains unknown. With the
growth of HIV clinical treatment and prevention trials internationally, examining such
associations using a standard measure can allow quality of life to be used as an outcome in
monitoring HIV treatments.
ACTG A5175, “A Phase IV, Prospective, Randomized, Open Label Evaluation of the
Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse
Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-
Infected Individuals from Resource-Limited Settings (PEARLS) Trial,” enrolled 1,571
patients with HIV from 46 study locations in nine countries. Participants were from Africa
(Malawi, South Africa, Zimbabwe), Asia (India, Thailand), South America (Brazil, Peru),
Haiti, and the United States. It is one of the first large-scale multi-country HIV treatment
trials, comparing the effectiveness of 3 three-drug combinations in treatment-naïve HIV-
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infected individuals. The diversity of patients and settings allows for a unique opportunity to
examine quality of life data from participants when entering the trial and its correlates to
disease severity and person characteristics. The analysis examined quality of life indicators
from the baseline assessment prior to initiating ART across diverse settings.
Methods
Study Participants
Eligible subjects were men and women ≥18 years with documented HIV-1 infection, CD4+
lymphocytes <300 cells mm−3, Karnofsky performance score ≥70, and ≤7 days of
cumulative prior antiretroviral therapy prior to study entry (with the exception of limited
prevention of Mother To Child Transmission (pMTCT) therapy). Women of reproductive
potential were required to be non-pregnant and, if sexually active, agree to effective
contraceptive use. Persons with serious chronic, acute, or recurrent infections must have
completed at least 14 days of therapy prior to study entry and be clinically stable. Persons
with absolute neutrophil count <750 mm−3, hemoglobin <7.5 g/dL, platelet count <50,000
mm−3, calculated creatinine clearance <60 ml/min, aspartate transaminase (AST), alanine
transaminase (ALT) or alkaline phosphatase >fivefold above the upper limit of normal, total
bilirubin >2.5-fold above the upper limit of normal, clinical pancreatitis within 3 years,
bradycardia (<40 min−1) or a history of untreated active second or third degree heart block
were excluded from participation. The study was approved by the institutional review board
at each participating institution. Written informed consent was obtained from study
participants following the human experimentation guidelines of the U.S. Department of
Health and Human Services [17].
Data Collection
At PEARLS study entry, clinical assessments were performed and safety laboratory tests,
plasma HIV-1 RNA and CD4+ lymphocyte counts were obtained. Quality of life was
measured with the ACTG SF-21, which was adapted from the SF-21 [18] by the ACTG
Outcomes Committee with feedback from local community members and site investigators.
The ACTG SF-21 was originally adapted from the Medical Outcomes Study HIV Health
Survey (MOS-HIV), a measure with well-established reliability and validity [19].
Modifications included removing one item (a visual 0–100 analog scale assessing overall
health perceptions), simplifying items, and re-wording items for clarity. The measure
consists of 20 items that assessed 8 domains: general health perceptions, physical
functioning, role functioning, pain, social functioning, mental health, energy/fatigue, and
cognitive functioning. Across all domains, higher scores indicated better quality of life. For
example, a low score in the physical functioning domain indicates poor physical
functioning, a high score in the energy/fatigue domain indicates high vitality, and a high
score in the pain domain indicates less pain. All questions covered the previous 4 weeks. At
all sites, the measure was translated and back-translated to ensure accuracy. The measure
was administered in a face-to-face interview by study nurses in the local language.
General Health Perceptions
This three-item subscale asks patients to rate their general health, resistance to illnesses, and
health outlook. This subscale has been validated by Davis and Ware [20] and Stewart and
Ware [21].
Physical Functioning
This is a subscale with four items inquiring about physical limitations that range from minor
to severe, including lifting heavy objects or participating in strenuous sports, walking uphill
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or climbing a few flights of stairs, and being able to eat, dress, bathe and use the toilet by
oneself.
Role Functioning
Using two questions, this subscale asks participants if their health negatively impacts their
ability to perform at a job/ school, or to work around the house.
Pain
The two items of this subscale assess intensity of physical pain and degree of interference
with daily activities [22].
Social Functioning
This subscale consists of two items that ask participants to what extent their social activities
have been limited by their health [23].
Mental Health
The three items in this subscale assess anxiety, depression, and overall psychological well-
being [24]. Two questions are reverse coded to control for response set effects.
Energy/Fatigue
This subscale assesses vitality; one item is reverse coded to control for response set effects.
Cognitive Functioning
Consisting of three items, this subscale assesses a participant’s level of difficulty with
reasoning/solving problems, being attentive, and remembering.
Data Analysis
Means and standard deviations summarized outcome measurements overall and within
subgroups. Differences among categories of CD4+ lymphocyte counts and plasma HIV-1
viral load for each quality of life domain were compared using both the Kruskal–Wallis test
for unordered alternatives among subgroups and the Jonckheere–Terpstra test for ordered
alternatives among ordinal subgroups. Significance for these tests was assessed at a nominal
0.05 level without adjustment for multiple comparisons.
To compare quality of life domains by country, permutation testing was used to account for
the multiplicity issue of 36 pair-wise comparisons among 9 countries. As there is no natural
referent country, elucidating how countries differ requires an omnibus (8 degree of freedom)
test comparing across all countries to reject equanimity. Alternatively, Monte Carlo samples
(size 10,000) of the null distribution (i.e., no differences between the two countries being
compared) were assembled by randomly permuting country assignment among participants.
The normalized difference (T-statistic) of the observed pair-wise comparison was compared
to the simulated null distribution; a 2-sided P value was calculated by the number of times
the observed difference was more extreme than the critical value of the largest pair-wise
difference from the simulated null distribution.
Results
Demographics
The observed sample consisted of 1,563 of 1,571 participants (8 missing baseline quality of
life data) enrolled between May 2005 and August 2007 from the United States and eight
Safren et al. Page 4













countries in resource-limited areas of the world (Table 1). Overall, the sample contained
slightly more men (52.7%) than women (47.3%) and was predominately young.
Plasma HIV-1 RNA Viral Load and CD4+ Lymphocyte Counts
Baseline quality of life was associated with both plasma HIV-1 RNA and CD4+ lymphocyte
count categories as shown in Tables 2 and 3. Although viral load and CD4 varied by
category at baseline, quality of life in each of the domains was relatively high, indicating
low levels of limitations and distress.
Four quality of life domains varied significantly across viral load categories: general health
perception (P = 0.002), physical functioning (P < 0.001), role functioning (P = 0.015), and
energy/fatigue (P < 0.001). More specifically, a trend of decreasing quality of life was
observed for increasing plasma HIV-1 RNA viral load category for three quality of life
domains: physical functioning (P = 0.004), role functioning (P = 0.019), and energy/fatigue
(P = 0.044).
All quality of life domains varied significantly across CD4+ lymphocyte count categories
(all P ≤ 002). Trend tests revealed significantly increasing quality of life scores across
increasing CD4+ lymphocyte count categories for each of the quality of life domains (all P
≤ 0.005).
Associations of Quality of Life Domains to Sex and Age
Only the social functioning subscale varied by sex, with men having greater impairments
than women (P < 0.002), and only the physical functioning subscale varied by age category
(P < 0.002), with physical functioning decreasing as age increased (data not shown).
Quality of Life Domains by Country
Quality of life domains varied significantly by country; rankings of quality of life domains
by country and significant differences between countries are shown in Table 4. For general
health perceptions, India’s and South Africa’s mean scores were significantly higher than 6
other countries. Haiti’s mean general health perception was significantly lower than the 3
top-ranked countries, and Malawi’s mean was significantly lower than all countries in the
top 5. In the domain of physical functioning, Peru’s and India’s mean scores were highest,
while Brazil and the U.S. ranked significantly lower than all 5 of the top-ranked countries.
For role functioning, Zimbabwe’s, Thailand’s, and India’s mean scores were highest, while
Peru had significantly lower role functioning scores than all other countries. For pain,
Zimbabwe’s mean score was highest (least pain) while Peru, India, South Africa, Haiti, and
Thailand also scored significantly higher (less pain) than the countries with the lowest-
ranked mean scores. In the domain of social functioning, India, Zimbabwe, and South Africa
ranked significantly higher than the four lowest-rated countries, while the U.S. ranked
significantly lower than every other country. In terms of mental health, Zimbabwe, South
Africa, India, Thailand, and Malawi ranked significantly higher than the four countries with
the lowest-ranked mean scores. For energy, Zimbabwe’s and Thailand’s means were
highest; the U.S. had significantly lower energy scores than every other country. Finally, for
cognitive functioning, India, South Africa, and Zimbabwe ranked significantly higher than
the four lowest-ranked countries. In addition, Haiti and Peru had significantly higher scores
than the lowest-ranked country, the U.S.
Discussion
In the first study evaluating established quality of life measures among clinical trial
participants from diverse international settings, we found marked variability in the measure
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across countries. For all measures of quality of life, higher CD4+ lymphocyte count category
was associated with higher quality of life performance scores. For several quality of life
domains (general health perception, physical functioning, role functioning, and energy/
fatigue), higher viral load was associated with lower scores. The more consistent association
with CD4 than viral load is expected because CD4 is an overall indicator of immune
function and more of an indicator of disease progression, whereas viral load is an indicator
of the amount of virus in the system, not an indicator of the effects of the virus [25, 26].
These data provide preliminary evidence for the utility of this quality of life assessment
across diverse settings.
Comparisons of the quality of life subscales by country, however, provided a complex set of
findings, which differed across the quality of life domains. There was no single country
consistently showing the highest quality of life subscale scores across domains, though, with
one exception, India was consistently in the top 3. U.S. quality of life scores were not
significantly higher than other countries, and for many domains, were ranked lowest. This
may be partially attributable to selection bias regarding disease stage. Twenty-two percent
(22%) of U.S. subjects had CD4+ lymphocyte counts <50 compared to an average of 13%
overall and 19% of U.S. subjects had been diagnosed with AIDS compared to 8% overall.
Treatment-naïve subjects consisted mostly of late presenters in the U.S., whereas at other
sites, the pool of treatment-naïve potential subjects was more diverse in terms of disease
progression. Within-country studies of the quality of life measure may further identify
contributors to the various domains of quality of life within a given culture. In addition,
future research may wish to address the clinical significance and magnitude of differences
by country or across quality of life subscales.
There are several limitations of the present study. First, this analysis was cross-sectional.
Longitudinal follow-up data from the PEARLS trial will allow for determining the timing of
CD4 and viral load changes with respect to improvements or decrements in quality of life as
measured by the ACTG SF. Second, individuals with Karnofsky scores <70 were excluded,
thereby limiting generalizability of the study. Additionally, the study sample was not a
representative sample of HIV-infected persons in participating countries, thereby also
limiting the generalizability of the between-country variations in quality of life. Third, the
process of adapting the ACTG-SF measure of quality of life occurred through consensus
meetings across site investigators and ACTG behavioral scientists, but pilot testing and an
iterative process of scale development was not possible in the context of a clinical trial.
Finally, the ACT-SF measure has not been formally validated in many of the local languages
used in this study. However, the reliability and validity of MOS-HIV, the measure upon
which the ACTC-SF was based, has been assessed and found to be comparable to the
original measure in French, German, Italian, Dutch, UK English translations [27], Thai [28],
Chinese [29], and most recently Greek [30], implying that the measure remains reliable and
valid across a variety of languages. Regardless, future studies should address measure
validation across languages.
This report provides initial evidence for the ability of the ACTG SF-21 scale to be used in
multi-national studies, as well as potential for use as a baseline to compare to current and
future cohorts. Because of the associations of subscales to CD4 and viral load, further
investigations of the measure may provide supporting evidence that provision of ART not
only reduces the medical effects of HIV but also improves functioning and quality of life.
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Table 1
Demographic information for the sample
Percentage (N = 1,563)
Gender
   Male 52.7
   Female 47.3
Age
   <20 <1
   20–29 27
   30–39 44
   40–49 22
   50–59 6
   60+ 1
Country of origin
   Brazil 14.8
   Haiti 6.4
   India 16.3
   Malawi 14.1
   Peru 8.6
   Thailand 6.4
   South Africa 13.4
   United States 13.4
   Zimbabwe 7.0
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